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Abstract
Next generation sequencing has provided the ability to screen for novel microRNA (miRNA) biomarkers in biofluids
of patients with cancer. Extravesicular vesicles in the peripheral blood, known as exosomes, provide a reliable source
of miRNAs for disease biomarker detection. The molecular content of exosomes, readily available in body fluids
such as blood, urine and saliva, is highly specific and a powerful biomedical tool. Exosomes generated during
tumorigenesis and derived from cancer cells provide cancer fingerprints, detectable in peripheral blood. In addition,
since cancer exosomes are messengers for signaling and alteration of the tumor microenvironment, it is no surprise
that cancer features such as angiogenesis, chemoresistance and metastasis are associated with them, and their ability
to facilitate the formation of a pre-metastatic niche as a primer for implantation of circulating tumor cells. The aim
of this paper is to provide a review of the state-of-the-art of exosomes in cancer research, their role in cancer niche
development with clinical correlation as biomarkers for cancer diagnosis and prognosis, as well as their future use
in exo-therapy in the era of precision oncology medicine.
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Introduction
Newer and less toxic treatments for cancer are
desperately needed as the group of cancer survivors
teaches us about long-term effects of current standard
chemotherapy. In addition, identification of novel
minimal invasive biomarkers for early cancer detection
may improve treatment outcomes. Cancer biomarkers
are informative of the pathological status for diagnosis
and prognosis of a disease and have received increasing
attention in cancer research for screening, early
diagnosis and detection of relapse of solid tumors.
One such biomarkers group is a class of small noncoding RNAs, termed microRNAs (miRNAs). An
intriguing new strategy for biomarker detection is
analysis of miRNAs content of exosomes, isolated from
body fluids of cancer patients. Exosomes are
extracellular lipid microvesicles (40-100 nm), secreted

by nearly all cells in body fluids (1) such as peripheral
blood (2), urine (3), saliva, breast milk (4),
cerebrospinal fluid and malignant effusions (5). They
contain functional biomolecules including oncogenic
proteins, lipids, ssDNA and dsDNA (6) and are
perceived to be carriers of unique signaling molecules
like miRNAs (7). By membrane invagination of late
endosomes, exosomal vesicles are formed that contain
cytosolic content of the cell of origin in healthy as well
as pathological cells (8). Upon release in the body fluid
microenvironment, the exosomes represent the
fingerprint of the releasing cell type that can be
transferred to target cells. The vesicle-associated RNA
is called exosomal shuttle RNA (esRNA) that includes
miRNAs as well as mRNA and are functional in target
cells where they effectively silence genes (9, 10).
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Twelve years after the first major review (8), exosome
research is about to explode especially in the field of
cancer pathophysiology (11, 12). As vehicles of
intercellular communication, exosomes play important
roles in cancer tumorigenesis and metastatic disease
(13). Tumor-specific exosomes are mediators of
oncogenesis as they exhibit tissue-specific addresses
and the ability to disturb the exquisite precise regulatory
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mechanism of secretion and adhesion might contribute
to cancer pathogenesis (i.e. mail delivered to the wrong
address). The spectrum of current scientific interest in
exosomes ranges from studying functions and pathways
of exosomes to utilizing them in diagnostics and
development of new therapeutics (14, 15), some of
which are already in Phase I clinical trial for melanoma
(16).

Figure 1: Exosomes Biogenesis in Cancer
(A) Budding: Exosome biogenesis in the cell for origin (normal and cancer cell) is a two-step process with formation
of intraluminal vesicles by (a) endocytic budding of the cell membrane with trapping of extracellular material
intraluminally with formation of endosomes. Through a second inward budding of the endosomes with trapping of
a portion of the cell’s cytoplasm, (b) multivesicular bodies containing exosomes are formed. (B) Fusion: After fusion
with the cell membrane of the target cell (c), exosomes release their cargo (d). ESCRT: Endosomal Sorting Complex
Required for Transport; TSAP6: Tumor Activated Pathway-1 (p53 target gene); RabGTPases: exocytic pathway
family members. Blue vesicles indicate endosomes in normal cells; Yellow vesicles indicate exosomes as regulators
of normal homeostasis; Orange vesicles indicate exosomes as regulators of tumorigenesis.
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Exosomes biogenesis in cancer
Exosomes were first identified in 1985 as small vesicles
floating in supernatant of in vitro cultured adherent cell
layers that were associated with plasma membrane
enzymatic activity of the parent cells (17, 18).
Historically however in the late 70s, extracellular
vesicles have been isolated from physiological media
such as seminal plasma and prostatic fluid, hence called
“prostasomes” after the organ of origin ie. prostate (19,
20). Prostasomes have been studied for their dual role
in normal reproduction as well as malignant prostate
growth (21, 22). Exosome biogenesis is a two-step
process with formation of endosomes by invagination
of the cell membrane with trapping of extracellular
material intraluminally. Consequently, a second inward
budding with trapping of a portion of the cell’s
cytoplasm on multiple loci of the endosomal membrane,
gives rise to intraluminal vesicles (forming the
multivesicular body, MVB) that, after fusion between
the membrane surrounding the MVB and the cell
surface plasma membrane, are released as exosomes
extracellularly. Exosomes are shed in the extracellular
environment allowing for re-uptake by target cells to
deliver their cargo (8) (Fig. 1). The 2013 Nobel Prize in
Medicine was awarded for the discovery of the
molecular principles that govern how this cargo is
delivered to the right place at the right time (23-25). By
repetitive ‘budding’ (the vesicle pinches off from a
‘donor’ membrane) and ‘fusion’ (the membrane of the
vesicle merges with the target membrane) of exosomes,
a beneficial vesicle transfer process is created with an
important role in intracellular and extracellular
physiology (23). Exosome concentrations are increased
in body fluids of cancer patients compared to healthy
controls, implicating their role in tumor growth and
metastatic spread (26, 27). Two mechanisms have been
proposed: first, cancer cells might increase their
exosome biogenesis by upregulation of tumor activated
pathway-1 (TSAP6 - a direct p53 transcriptional target
gene) (12, 28, 29); Second, exosome secretion by
tumors is induced via the exocytic pathway by RabGTPases family members, more precisely the Rab27B
protein (Fig.1) (30, 31).
Molecular markers of exosomes are the surface
tetraspanins CD9, CD63, CD81, CD82 and CD151 in
addition to major histocompatibility complex (MHC)
class I and MHC class II proteins (32). Several detailed
protocols are readily available that describe exosome
isolation methods using different techniques:
ultracentrifugation,
OptiPrep
density
gradient
centrifugation, ExoQuick and total exosome isolation
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precipitation (1, 33). Exosomal equipment such as
lipids, proteins, miRNA and messenger RNA (mRNA)
are concealed by the cancer source cell in exosomes
and, once absorbed by target cells of different lineage,
are capable of inducing pathways involved in cancer
initiation, support and progression (12). The proteomic
content of exosomes is very specific, combining
common plasma membrane (cell surface receptors) and
cytosolic proteins as well as distinct cell-type specific
proteins (34, 35). Heat shock proteins (HSP-70), which
are known to have immunological properties and the
ability to induce dendritic cells, have been identified as
part of the cytosolic proteins. Therefore, exosomebased vaccines may be a promising new strategy as
immunotherapy in cancer (36, 37).
MicroRNAs are small, non-coding RNA molecules
implicated in post-transcriptional gene expression
regulation. Since exosomal miRNA (exo-miRNA) can
be transferred to target cells and translated into
functional proteins, they have appropriately been called
“exosomal shuttle RNA” (esRNA) (7). Moreover, exomiRNAs are protected from degradation by RNAse
enzymes in the circulation (38)(Fig.1). Because of the
complexity of tissue/cell type specific proteins present
in exosomes a compendium called ExoCarta
((http://exocarta.ludwig.edu.au) of the most commonly
found exosome-related proteins (n=4,563), lipids
(n=194), mRNAs (n=1,639) and miRNAs (n=764) was
established as a resource for exosomal research (39, 40).
In addition, two new recent initiatives are free available
online as reference databases for exosomes
investigators: Vesiclepedia (a compendium for
extracellular vesicles with continuous community
annotation) (41) and EVpedia (http://evpedia.info) (an
integrated database of high-throughput data for
systemic analysis of extravesicular vesicles) (42, 43).
Hananan and Weinberg conceptualized the hallmarks of
cancer transformation (growth, apoptosis, migration
and angiogenesis) as manifestations of a somatic
mutational theory (44). However, Sonnenschein refuted
this concept and promotes cancer as a tissue-based
disease whereby carcinogenesis is due to alteration of
the reciprocal interaction between cells and their
microenvironment, which includes endothelial cells,
immune cells, extracellular matrix, fibroblasts and
mesenchymal cells, mediated by signaling molecules
such as RNA and miRNA (45). End-stage disease in
cancer patients seems to support the latter, where
multiorgan failure may originate from widespread
dissemination of tumor cells derived from a single
primary tumor. Since cancer-derived exosomes carry
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both genomic and proteomic material, they may interact
as propagators of the cancer niche, with pathways
supported by both theories (Fig. 2).
Exosomes: the language of the stem cell niche?
One of the proposed disparities between a normal stem
cell and a cancer stem cell is the difference in reliance
on the stem cell niche, a specialized habitat to ensure
their survival (46). miRNA regulates stem cell
maintenance as well as oncogenesis within the niche, by
promoting or inhibiting proliferative signaling. Homing
and recruitment molecular mechanisms from the normal

Review

stem cell can be seized by cancer stem cells, as tools for
invasion and metastasis (47, 48). Cancer-cell derived
exo-miRNAs are cast within exosomes into the
circulation and body fluids. Bearers of the cancer
signature to surrounding and long-distance cells,
exosomes communicate signals between stem cells and
the microenvironment as translators of the language of
the cancer cell niche. This language is a two-way
communication, whereby according to the “seed and
soil” theory (49), miRNA from the ‘seed’ can alter the
‘soil’ and vice versa (48, 50).

Figure 2: Exosomes and the Cancer Niche
(A) Exosomes are secreted in the cancer niche by normal supportive cells of the microenvironment (endothelial
cells, mesenchymal stem cells, fibroblasts, bone marrow stem cells) as well as by the cancer cells. (B) During the
homeostatic process of self-renewal, exosomes may play a role in stem cell maintenance as well as terminal
differentiation. (C) Exosomes as propagators of oncogenesis (a) at the primary tumor site, (b) at the pre-metastatic
niche, and (c) in metastatic disease. Cancer niche: Blue cancer cells in cancer niche (A) indicate dormancy; Red
cancer cells in primary tumor environment (a) indicate activation.
- 14 -
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The secretory Rab GTPases Rab3D, Rab27A and
Rab27B are main regulators of exocytosis (51). Rab
GTPases constitutive exocytic trafficking has been
involved in regulation of exosomal matrix
metalloproteases (MMP), which modulate the matrix in
the target organ necessary for cancer cell invasion (52).
Since Rab27B exo-miRNA levels are significantly
higher in patients with invasive breast cancer (estrogen
receptor-positive with nodal involvement), they might
serve as a biomarker of ER-positive breast cancer with
poor prognosis (30).
In hematological malignancies, exosomes are shed by
normal blood cells (platelets, endothelial cells,
leukocytes and monocytes) as well as by leukemia cells
(53). B-cell chronic lymphatic leukemia (CLL) is a
clonal B-cell disorder driven by constitutional
expression of the receptor tyrosine kinase AXL (RTKAXL). Circulating exosomes in plasma of CLL patients
are at higher levels than in healthy controls and carry
phosphorylated RTK-AXL, which are able to activate
the AKT-target rapamycin signaling pathway in CLL
bone marrow stroma cells (27). Chronic myeloid
leukemia (CML) is a clonal myeloproliferative disease
caused by Bcr-Abl oncoprotein-driven tyrosine kinase
activity (Philadelphia chromosome). Exosomal
crosstalk between CML cells and their bone marrow
niche induces angiogenesis via exosomal release of
interleukin-8 in vitro (54). Moreover, transferred BcrAbl DNA from the K562-CML cell line induced a
CML-phenotype
in
mice,
emphasizing
the
pathophysiological role of exosomal tumor genes
transfer in leukemogenesis (55).
In acute myeloid leukemia (AML), exosome trafficking
alters the microenvironmental niche by transferred
mRNA, reprogramming the bone marrow during
invasion of AML (56). Exosomes also play a role in the
immune surveillance by natural killer (NK) cells,
building a protective shield for human leukemia nicheinvaders. NK cell surveillance is an important
physiological tool of cancer restraint that is curbed in
patients with AML because blast-derived exosomes
suppress NK-cell activity using the TGF-β1 pathway
(57). Moreover, changes in exosomal TGF-β1 content
may have clinical predictive value for the outcome of
chemotherapy (58).
Exosomes in the pre-metastatic niche
Once tumor cells leave the protective niche of origin,
additional conditions must be met for successful
sprouting in foreign soil i.e. growth of metastatic
disease (59, 60). One of the conditions is the presence
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of a long-distance signaling system conducive to the
creation of an adaptive environment for “traveling”
tumor cells. This signaling system needs to be able to
alter expression of growth factors (VEGF-1), matrix
metalloproteinases (MMP-9) and adhesion molecules
(integrin VLA-4) to allow the establishment of a premetastatic niche at a distance from the primary tumor
location (61). An emerging common theme in solid
tumor oncogenesis is the evidence that exosomes drive
pre-metastatic niche formation (62, 63). Highly
metastatic melanoma exosomes can educate bone
marrow progenitors towards a pro-vasculogenic
phenotype at a pre-metastatic site via the tyrosine kinase
receptor MET. Peinado et al identified an exosomespecific melanoma signature in patients with clinical
correlation to advanced disease stage and poor
prognosis (64). Modulation of host extracellular matrix
degradation by tumor exosomes promotes motility and
allows for recruitment and invasiveness of circulating
tumor cells to the pre-metastatic niche (65). Breast
cancer exosomes are involved in leading the ‘metastatic
exodus to the promised niche’ (66). Exosomes produced
by breast cancer cells are taken up by stromal fibroblasts
and reciprocally cancer-associated fibroblast-derived
exosomes stimulate breast cancer cell motility and
metastatic behavior via autocrine Wnt-11 signaling (6769). Tumor-initiating cells that express the
mesenchymal cell marker CD105 in human renal cell
carcinoma release exosomes that stimulate the
formation of the lung metastatic niche in mice (70).
Recent studies in cancer cell lines show that ovarian
cancer cell invasiveness correlates with excessive
exosomal let-7 miRNAs (71) and a metastatic gastric
cancer cell line releases let-7 miRs via exosomes in the
extracellular environment to promote tumor growth. In
normal homeostasis, let-7 controls cell proliferation by
negative regulation of Ras GTPases but constitutively
activated Ras mutations are common in solid tumors
(72). The exact mechanism by which exosomal let-7
regulates cancer growth remains to be elucidated.
Proteomic profiling of exosomes from human primary
and metastatic colon cancer revealed differential
expression of key metastatic factors such as the tyrosine
kinase receptor MET, implementing their role in
metastatic niche configuration (73).
Exosomes: novel biomarkers in cancer diagnostics
In order for biomarkers to be useful in the clinical
setting of cancer patients, they must: 1, be easy
accessible by minimal invasive procedures for
repetitive sampling; 2, represent the signature of the
cancer of origin; 3, be distant travelers to deliver their
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protected cargo; 4, gain easy and specific entry into
target cells; 5, carry the machinery to interfere with
intra- and intercellular differentiation signaling; 6,
reflect disease-stage and exhibit changes in response to
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initiated treatment and last but not least 7, be amenable
to high-throughput screening in larger patient
populations with a reference database available (Table
1).

Table 1: Exosomes as Cancer Biomarkers
Cancer Biomarker Criteria

Exosomes as Cancer Biomarkers



Easy accessible by minimal invasive
procedures for repetitive sampling



Body fluids (1, 9, 74)



Signature of the cancer of origin



Exo-miRs (75, 76)

Distant travelers for safe cargo delivery





Rab GTPases-regulated vesicle trafficking (51)
p53-regulated exosome release (77)
Exo-miRs in blood are RNase protected (38, 69)







Target cell-specific entry



Phosphatidylserine exosome uptake signal in NK
cells (42)
Surface expression of adhesion tetraspanin-integrin
complexes on exosomes (66, 78, 79)



Interference with intra- and intercellular
differentiation signaling





Exosomal shuttle RNA (esRNA) (7)
Immunomodulation (80, 81)
Cancer dormancy (10)



Disease-stage specific and treatment
responsive




Exo-predictive biomarker with chemo
responsiveness (82)
Exo-transfer of multidrug resistance (83, 84)



High-output screening tool



NGS of exo-miRNAs (85, 86)



Reference database available





Exocarta (40)
Vesiclepedia (41)
EVpedia (42, 43)

Exosomes
are
key-players
in
intercellular
communication, and since their host-cell derived cargo
can regulate cellular signaling, they are prime
candidates for the role of traveling messengers to
deliver that cargo to local or distant target cells (13, 87).
The oncogenic cargo of cancer-related exosomes
contains bioactive molecules including DNA, mRNA
and miRNAs (hence these cancer-related exosomes are

often referred to as oncosomes)(88). Noncoding
transcripts such as miRs are part of the exosome
repertoire by which oncosomes assist in the process of
tumor promotion by modulating the microenvironment
into receptive metastatic niches. Proof of concept that
exosomes represent the signature of the cancer of origin
was demonstrated in a xenograft mouse model of
human lung cancer cells, labeled with human CD63-
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green fluorescent protein (GFP). hCD63-GFP
exosomes were identified in blood and saliva of tumorbearing mice, suggestive of the link between distal
tumor progression and biomarker discovery in saliva
(76). Entry into target cells seems not to be an at random
event either. Human brain tumors (gliomas) express an
oncogenic form of the epidermal growth factor receptor,
known as EGFRvIII. EGFRvIII can be ‘shared’ by
glioma cells via horizontal transfer by oncosomes with
transfer of oncogenic activity and promotion of the
cancer phenotype (89). However, identification of the
exosomes-target anchorage and internalization
components remains greatly elusive, although heparinglycan proteins and integrins on the exosomal
membrane surface have been suggested to play a role
(78, 79). The packaging of their molecular load is
tissue-specific and strictly regulated by a group of
proteins that form the endosomal sorting complex,
required for transport (ESCRT) (Fig.1) (90, 91).
Because this highly specific packaging process allows
exosomes to carry the signature of the cancer cell of
origin into the blood stream and supporting stroma, it
makes them perfect biomarkers for cancer diagnostics
with clinical correlation to disease stage (26, 82). Nextgeneration deep sequencing (NGS) facilitates highthroughput profiling of miRNAs in biological fluids
making this approach a viable screening tool to detect
miRNAs biomarkers. NGS has been used to profile
miRNAs in exosomes, which appear to provide a
consistent source of miRNAs suitable for cancer
biomarker detection (86). For example, NGS of
exosomal transcripts in breast cancer cell lines revealed
their cell of origin, confirming their utility as potential
biomarkers in breast cancer (85). In addition, exosomal
RNA is protected from degradation by circulating
RNAses of the blood stream assuring reproducibility
and stability (38, 69). However, Argonaute2 (Ago2)
complexes carry a population of circulating miRNAs
independent of exosomes in human plasma and the
circulating Ago2 complexes have been suggested as
another mechanism responsible for the stability of
plasma miRNAs. This information is important for the
development of biomarker approaches based on
analysis of circulating miRNAs (92). A consensus
needs to be reached on dependable isolation methods
for exosome biomarker research (74). Reproducible
protocols that obtain the purest exosome fractions for
downstream RNA profiling with lack of contaminating
Argo2-complexes would meet the standards of clinical
care (33, 93, 94). Since exosomes can meet all proposed
biomarker criteria, they have been recognized as
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suitable biomarkers in cancer diagnostics for solid
tumors as well as hematological malignancies (Table 2).
Exosomes as cancer therapeutics – ExoDrug
Ideal cancer therapeutics should exhibit interference
with tumor growth and invasiveness as well as
circumvent multidrug resistance (MDR) in order to
obtain remission and effectiveness in cancer immune
surveillance to prevent relapse. Exosomes have been
investigated as specific delivery tools of functional
molecules to the microenvironment and their uptake by
target cells has been confirmed by labeling with
fluorescent
dyes
(GFP,
PKH,
DiOC18),
immunofluorescence and flow cytometry (15). Because
exosomes are capable of instigating an immune
response (likely through the actions of Hsp70 on the
exosomal surface – (95)), an exciting field of exosomal
cancer immunotherapy is burgeoning (80, 81, 96). Most
studies evolve around the application of dendritic cellderived exosomes (DEX) that have been pulsed with a
tumor antigen (12, 97). DEX harbor functional MHC
complexes capable of eliciting T-cell immune (CTL)
responses and tumor rejection. This concept was
translated in a first Phase I clinical trial in late stage
melanoma patients whereby autologous exosomes were
pulsed with MAGE3 peptides for vaccination (16). This
study highlights the feasibility of ExoDrug based on the
properties of: 1/ large scale exosome production, 2/
safety of exosome administration in a clinical setting
and 3/ minimal toxicity. Antileukemia immunity was
demonstrated in vitro, when exosomes from NB4 cells
(a human acute promyelocytic leukemia (APL) cell
line) presented leukemia antigens to dendritic cells with
the help of ICAM1 and Hsp70, hence inducing effective
cytotoxic activity to kill leukemia cells (95). Ascites has
been proposed as another rich source of autologous
tumor-exosomes (TEX) in ovarian cancer and
colorectal cancer patients (81, 98, 99). In colorectal
cancer patients, exosomes plus granulocyte monocytic
colony stimulating factor (GM-CSF) injections induced
beneficial tumor-specific CTL responses, thereby
demonstrating that clinical exo-therapy is well
tolerated. One of the main causes of disease relapse in
cancer patients is phenotypic changes in the tumor that
result in multidrug resistance (MRD). Exosomemediated communication of drug resistance among
tumor cells and between tumor cells and
microenvironment habeen suggested as a mechanism of
MRD (83, 84) and exosomal blockages of drug
resistance-transfer could mark an improved disease-free
survival. Another intriguing approach for ExoDrug
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Table 2: Representative Studies on Exosomes as Biomarkers in Cancer Diagnostics
Primary Tumor/
Exosome source

Metastatic
Melanoma

Lung Cancer

Exosomal Biomarker
Biofluid

References
Protein

Serum

miRNA

MRD-9 and GFP78

Guan et al (100)

TYRP2, VLA-4,
HSP70, HSP90*

Peinado et al (64)
miR125b

Alegre et al (101)

miR-378a, miR-379, miR139-5p, and miR-200b-5p

Cazzoli et al (102)

Serum
Yamashita et al
(103)

EGFR

Serum

Renal Cell
Carcinoma

Prostate Cancer

miR-1246,miR-4644
miR-3976,miT-4306

Madhavan et al
(104)

MET, CD104

Pancreas Cancer

Ovarian Cancer

CD44v6,
Tspan8,EpCam

Saliva

Apbb1ip, Aspn,
BCO31781, Daf2,
Foxp1, Gng2

Serum

EpCam

Urine

Urine

Lau et al (105)
miR-21, miR-141, miR-200a,
miR-200c, miR-200b, miR203, miR-205, miR-214

MMP9, PODXL,

Taylor et al (26)

Raimondo et al
(106)

CAIX, AQP1, CP
PCA-3,
TMPRSS2:ERG

Nilsson et al (107)
miR34a*

Corcoran et al (82)

Plasma

miR-21

Corcoran et al (108)

Glioblastoma

Serum

Let-7a, miR15b, miR-16,
miR-19b, miR-21, miR-26a ,
miR-27ª ,miR92 ,miR93, miR320, miR-20

Skog et al (109)

Gastrointestinal
Cancer

Serum

Colon Cancer

Serum

Acute Myeloid
Leukemia

Plasma

Breast Cancer

Lindner et al (110)
Let-7a, miR-1229, miR-1246,
miR-150, miR-21, miR-223,
and miR-23a

Ogata-Kawata et al
(111)
Hong et al (58)

CD34

*clinical trial
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application is to outfox the uptake of exosomes by the
target cells at the cancer niche (52), hence impeding
TEX-initiating angiogenesis (112) in premetastatic niche
formation. Exosomal induced-PPARalpha-NF-kappaBAkt pathways may play a pivotal stimulatory role for
neovascularization, which is crucial in tumor growth and
maintenance (113). In addition, exosomes can activate
angiogenic programming of bone marrow derived
endothelial progenitor cells (EPC). Therefore, a potential
method for ExoDrug therapy could be exosomal
blockage of EPC instead of activation. Since TEX
support tumor maintenance via several different
mechanisms, mere removal of TEX from the patient
circulation by ultrafiltration through affinity binding
filters with exosomal ligands and TEX-specific
antibodies has been proposed as adjuvant cancer therapy
(114).

selective gene silencing of mitogen-activated protein
kinase 1 in human monocytes and lymphocytes (14). The
rapid and safe distribution of an exosome-encapsulated
anti-inflammatory drug, called curcumin, to the brain via
intranasal administration, might open new venues for
easy and non-invasive drug delivery in neuro-oncology,
bypassing the blood-brain barrier. Fluorescent labeled
intranasal delivered exosomes were visible in microglia,
suggesting cell uptake in the brain (118, 119) .

Nanomedicine explores the use of nano-particles for
therapeutic and diagnostic application - termed
theranostics- and exosomes are active participants as
nano-theranostic delivery agents for gene therapy (115).
The use of exosomes as drug delivery systems requires
pharmacokinetic
studies
of
circulation
time,
biodistribution, stability, cellular interaction and cargo
loading, lessons that can be learned from the liposome
field (74). RNA interference and gene transfer cancer
therapy looked promising as methods for effective
interruption of the cancer apparatus. However, one of the
main problems to be overcome is successful conveyance
of nucleic acids across the cell’s plasma membrane.
Bioengineered exosomes prepared through expression
vector transfection have declared themselves as perfect
exo-missiles for targeted gene delivery into cells derived
from different lineages (7, 116, 117). Plasma exosomes
have been used as gene delivery vectors to transport
exogenous small interference RNA (siRNA) that caused

Exosomes in cancer research is a promising new field in
translational medicine. Their use as clinical biomarkers
for cancer staging is already in Phase I trial for
melanoma. The International Society for Extracellular
Vesicles (ISEV) as a global society for researchers
around the world with interest in this field addresses best
practice in EV isolation and RNA packaging, low-input
high throughput sequencing and digital PCR to stress the
importance of a unified approach for clinical application.
Analysis and modification of cancer derived-exosome
content as well as creation of artificial-tailored exosomes
for drug delivery may lead to a novel era of cancer
therapeutics.

While the clinical application of exosomes for
therapeutic drug delivery in oncology is still immature,
issues regarding the understanding of exosomal
technology, large-scale production and in vivo toxicity
need to be addressed in order to develop lucrative and
cost-effective ExoDrug delivery systems.
Future Directions
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